Analysts remain positive on Eureka's growth prospects, owing to its high brand equity, capable management team, and asset-light business model.
HDFC Securities expects Eureka Forbes to deliver strong growth over FY25-28, with revenue, Ebitda, and profit rising at a CAGR of 14 per cent, 23 per cent, and 27 per cent, respectively
Nuvama has retained its 'Buy' tag on the stock, revising the target price to ₹750 per share from ₹700 per share, following a 32 per cent year-on-year jump in PAT to ₹61.6 crore in Q2FY26
Eureka Forbes Ltd, a health and hygiene product maker, on Thursday reported an increase of 31.77 per cent in its consolidated net profit to Rs 62.92 crore in the September quarter of FY26. The company had a net profit of Rs 47.74 crore in the July-September quarter a year ago, according to a regulatory filing by the firm, now controlled by private equity firm Advent International. Revenue from operations was up 14.7 per cent to Rs 772.07 crore during the September quarter of FY26. It stood at Rs 673.13 crore in the corresponding quarter a year ago. This is the "eighth successive quarter of double digit growth", said Eureka Forbes in its earnings presentation. Eureka Forbes' total expenses increased 12.55 per cent to Rs 693.0 crore in the September quarter on a year-on-year basis. Commenting on the results MD and CEO Pratik Pota said: "In an uncertain and evolving external environment, Q2 FY26 was an exciting milestone quarter for us. We delivered a strong revenue growth of 14.9 pe
Eureka Forbes share: Analysts see strong growth momentum, margin expansion, and deeper traction in after-sales services as catalysts for sustained shareholder returns.
Emkay initiated coverage on Eureka Forbes stock with a target price of ₹725, implying about 24 per cent upside.